BAYRY - Bayer Aktiengesellschaft

Other OTC - Other OTC Delayed Price. Currency in USD
19.30
0.00 (0.00%)
As of 1:54PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close19.30
Open19.18
Bid0.00 x 0
Ask0.00 x 0
Day's Range19.18 - 19.32
52 Week Range16.58 - 32.80
Volume142,203
Avg. Volume764,960
Market Cap72.51B
Beta (3Y Monthly)1.00
PE Ratio (TTM)10.46
EPS (TTM)1.84
Earnings DateN/A
Forward Dividend & Yield0.81 (4.38%)
Ex-Dividend Date2018-05-25
1y Target Est30.70
Trade prices are not sourced from all markets
  • Bayer Obtains Full Rights to Vitrakvi From Lilly's Loxo
    Zacks5 hours ago

    Bayer Obtains Full Rights to Vitrakvi From Lilly's Loxo

    Bayer (BAYRY) obtains full exclusive licensing rights for the global development and commercialization of Vitrakvi (larotrectinib) and BAY 2731954 (LOXO-195) from Loxo.

  • Reuters4 days ago

    Bayer gains full Vitrakvi rights from Eli Lilly's Loxo

    German drugmaker Bayer took full control of Vitrakvi, a drug used against a variety of cancers driven by a rare genetic mutation, in a deal with from Eli Lilly's Loxo Oncology. Bayer said on Friday it exercised a right to gain exclusive licensing rights for the global development and commercialization of Vitrakvi, also known as larotrectinib, under a clause in the initial collaboration deal with Loxo Oncology that provided for Loxo becoming a takeover target.

  • Reuters5 days ago

    Bayer stresses drug's tolerability in bid for prostate cancer market

    Bayer is banking on the mild side effects of its experimental prostate cancer drug darolutamide, as it prepares to take on established rival products by Pfizer and Johnson & Johnson. The drug, tested on early stage prostate cancer that does not respond to hormonal therapy, was shown to be safe to use with only fatigue as the most serious side effect, Bayer said on Thursday, citing a phase-three study that could be decisive for regulatory approval. Given the cancer is not yet spreading and patients are still relatively unburdened by the disease, a drug's tolerability is a key concern for the generally elderly men taking it, said Robert LaCaze, Bayer's head of oncology.

  • Moody's7 days ago

    Monsanto Finance Canada Co. -- Moody's withdraws Monsanto Company ratings

    Rating Action: Moody's withdraws Monsanto Company ratings. Global Credit Research- 12 Feb 2019. Approximately $1.0 billion of rated debt affected.

  • Reuters7 days ago

    FOCUS-How a Philippines regulator stymied DowDuPont's global seed launch

    WINNIPEG, Manitoba/CHICAGO, Feb 12 (Reuters) - A Philippines regulator poses an unexpected obstacle to DowDuPont's launch of a new line of genetically engineered soybeans in the United States as the company challenges Bayer AG's decades-long dominance of the U.S. seed market. China's January approval for imports of DowDuPont's Enlist E3 soybeans - amid the U.S.-China trade war - had raised hopes that the seeds would be broadly available for the U.S. spring planting season. It took more than five years for the company to win China's approval.

  • Reuters8 days ago

    How a Philippines regulator stymied DowDuPont's global seed launch

    WINNIPEG, Manitoba/CHICAGO (Reuters) - A Philippines regulator poses an unexpected obstacle to DowDuPont's launch of a new line of genetically engineered soybeans in the United States as the company challenges Bayer AG's decades-long dominance of the U.S. seed market. China's January approval for imports of DowDuPont's Enlist E3 soybeans - amid the U.S.-China trade war - had raised hopes that the seeds would be broadly available for the U.S. spring planting season. It took more than five years for the company to win China's approval.

  • Reuters8 days ago

    Exclusive: Monsanto wins arbitration ruling over royalties from Indian seed company

    German drugmaker Bayer AG's Monsanto unit has won proceedings against Indian seed maker Nuziveedu Seeds Ltd (NSL) in a royalty dispute, lawyers familiar with the matter said. The lawyers, who did not wish to be named as the decision was not public, did not disclose the terms of the arbitration ruling. Mahyco Monsanto Biotech (India) (MMB), a joint venture between Missouri-based Monsanto and India's Maharashtra Hybrid Seeds Co (Mahyco), "has received a favourable award from the arbitration panel in the proceedings against NSL and Prabhat", a Bayer spokesman said in an e-mailed statement when asked about the ruling.

  • Exclusive: Bayer's Monsanto wins arbitration ruling over royalties from Indian seed company
    Reuters8 days ago

    Exclusive: Bayer's Monsanto wins arbitration ruling over royalties from Indian seed company

    German drugmaker Bayer AG's Monsanto unit has won proceedings against Indian seed maker Nuziveedu Seeds Ltd (NSL) in a royalty dispute, lawyers familiar with the matter said. The lawyers, who did not wish to be named as the decision was not public, did not disclose the terms of the arbitration ruling. Mahyco Monsanto Biotech (India) (MMB), a joint venture between Missouri-based Monsanto and India's Maharashtra Hybrid Seeds Co (Mahyco), "has received a favorable award from the arbitration panel in the proceedings against NSL and Prabhat", a Bayer spokesman said in an e-mailed statement when asked about the ruling.

  • Reuters11 days ago

    Exclusive: Brazil soy farmers say Bayer violating court ruling in patent dispute

    Germany's Bayer AG is in violation of a Brazilian court order obliging it to deposit in escrow royalties paid by Mato Grosso state farmers for its Intacta RR2 Pro soy seed technology, farmers claimed on Friday. Instead of depositing the royalties in full, Mato Grosso grain growers association Aprosoja told Reuters that the value transferred by Bayer into an escrow account between July and December of last year represents just 4 percent of what state growers paid in the period. According to a legal filing dated Jan. 30 and seen by Reuters, Bayer, whose businesses include seed technology and agrochemicals, informed the court overseeing an ongoing patent dispute that it had deposited 11.22 million reais (£2.32 million) in the escrow account over the period.

  • Regeneron Q4 Earnings & Sales Beat on Strong Dupixent, Eylea
    Zacks13 days ago

    Regeneron Q4 Earnings & Sales Beat on Strong Dupixent, Eylea

    Regeneron's (REGN) earnings and sales surpass expectations in Q4 on solid Dupixent and Eylea sales.

  • Reuters13 days ago

    French, German farmers destroy crops after GMOs found in Bayer seeds

    Bayer said on Wednesday that farmers in France and Germany were digging up thousands of hectares of rapeseed fields after traces of genetically modified organisms (GMOs) banned for cultivation were found in seeds sold by the company. GMO crops are widely grown across the world, but they remain controversial in Europe, where very few varieties are authorised for growing and some countries like France have completely outlawed their cultivation, citing environmental risks. Checks by the French authorities during the autumn showed minute quantities of GMO seeds, estimated at less than 0.005 percent of the volume, in three batches of rapeseed seeds sold under the Dekalb brand, Catherine Lamboley, Bayer's chief operating officer for France, said.

  • Return of French farmer's case keeps Monsanto in legal spotlight
    Reuters13 days ago

    Return of French farmer's case keeps Monsanto in legal spotlight

    A decade-old lawsuit in which a French farmer with neurological problems accuses Monsanto of not providing adequate safety warnings for a weedkiller returns to court on Wednesday, adding to health claims faced by the Bayer-owned firm. Paul Francois, who says he fell ill after inhaling vapor from weedkiller Lasso in 2004, won rulings in 2012 and 2015 that found Monsanto liable for the intoxication, before France's top court overturned those decisions and ordered a new hearing. An appeal court in the southeastern French city of Lyon will hear arguments on Wednesday before giving its verdict at a later date.

  • U.S. jury orders Takeda to pay Bayer $155 million over hemophilia drug
    Reuters14 days ago

    U.S. jury orders Takeda to pay Bayer $155 million over hemophilia drug

    Jurors in the federal court in Wilmington, Delaware, reached their verdict on the seventh day of a trial after rejecting Baxalta's argument that the June 2016 patent on the treatment, Adynovate, was invalid. Bayer said the infringement arose from Baxalta's exclusive license agreement with Nektar Therapeutics, a San Francisco-based company that had done research with Bayer and knew about the patent, including through litigation in Germany.

  • AVEO Oncology Plunges on Delay in Filing Fotivda NDA With FDA
    Zacks18 days ago

    AVEO Oncology Plunges on Delay in Filing Fotivda NDA With FDA

    AVEO Oncology (AVEO) decides against filing NDA for Fotivda on recommendation of the FDA. The agency remains concerned with the overall survival data.

  • Market Exclusive21 days ago

    Market Morning: Huawei CFO Indictment, Bug In the Apple, Venezuela Choked, Bayer Blamed

    Asia Down on Huawei Robot Theft, Grand Jury Indictment Asian stocks are down, though not too heavily, on a grand jury indictment of Huawei Chief Financial Officer Meng Wenzhou. She was arrested in Canada late last year and has been waiting for an extradition request by the United States federal government, which now is reportedly […] The post Market Morning: Huawei CFO Indictment, Bug In the Apple, Venezuela Choked, Bayer Blamed appeared first on Market Exclusive.

  • U.S. judge to allow controversial evidence in Roundup cancer trials
    Reuters22 days ago

    U.S. judge to allow controversial evidence in Roundup cancer trials

    U.S. District Judge Vince Chhabria during a hearing in San Francisco federal court called his decision "probably most disappointing for Monsanto," the Bayer unit that manufactures the world's most widely used herbicide. The company denies allegations that glyphosate causes cancer and says decades of independent studies have shown the chemical to be safe for human use. Chhabria on Monday said plaintiffs could introduce some evidence of Monsanto's alleged attempts to ghostwrite studies and influence the findings of scientists and regulators during the first phase of upcoming trials.

  • Pricey GMO Soy Seeds Lose Luster as Farmers Hunt for More Profit
    Bloomberg25 days ago

    Pricey GMO Soy Seeds Lose Luster as Farmers Hunt for More Profit

    “Margins are so tight you are looking for anything you can to generate more dollars per acre,” Ruh, 50, said in a telephone interview from Sugar Grove, Illinois. Soybean futures in Chicago have slumped as much as 25 percent from a peak in March as China, embroiled in a trade war with the U.S., opted for Brazilian supplies following bumper crops in the Americas. Ruh said he decided on the switch in November.

  • Bayer AG unit head sees no merit in breaking up parent: FT
    Reuters26 days ago

    Bayer AG unit head sees no merit in breaking up parent: FT

    The head of Bayer's Crop Science unit, which combines Bayer's legacy pesticides unit with the acquired Monsanto business, sees no merit in splitting up parent company Bayer, he told the Financial Times. ...

  • Ultragenyx's Fatty Acid Disorder Candidate Succeeds in Study
    Zacks27 days ago

    Ultragenyx's Fatty Acid Disorder Candidate Succeeds in Study

    Ultragenyx releases encouraging top-line data from the phase III study on UX007 in patients with LC-FAOD.

  • Aerie's (AERI) Eye Care Candidate to Enter Clinical Studies
    Zackslast month

    Aerie's (AERI) Eye Care Candidate to Enter Clinical Studies

    Aerie's (AERI) Investigational New Drug Application for AR-1105 for the treatment of macular edema due to retinal vein occlusion is accepted by the FDA. The candidate will now enter clinical studies.

  • Regeneron (REGN) Sails Steady on Label Expansion of Drugs
    Zackslast month

    Regeneron (REGN) Sails Steady on Label Expansion of Drugs

    Regeneron's (REGN) performance has been steady in the past six months even as the overall industry declines.